A natural compound from a marine fungus can stop certain cancer cells from growing in lab tests, especially lung and skin cancer cells, at relatively low concentrations.
Claim Context
The meroditerpene aszonapyrone B (119), isolated from marine-derived Neosartorya laciniosa, exhibits cytotoxic effects against human breast adenocarcinoma (MCF-7), non-small cell lung cancer (NCI-H460), and melanoma (A375-C5) cell lines in vitro, with growth inhibition (GI50) values of 13.6, 11.6, and 10.2 µM, respectively, suggesting potential anticancer activity in these models.
“Compound 119 was the most active, exhibiting strong growth inhibitory activity against the three cell lines, with GI50 values of 13.6, 11.6, and 10.2 µM for MCF-7, NCI-H460, and A375-C5, respectively”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether aszonapyrone B causes tumor regression or improved survival in humans with relevant cancers
A double-blind, placebo-controlled Phase II RCT with 150 patients diagnosed with advanced non-small cell lung cancer, randomized to receive intravenous aszonapyrone B (5 mg/kg weekly) or placebo for 12 weeks, measuring tumor size (RECIST criteria), progression-free survival, and quality of life as primary endpoints
Whether exposure to aszonapyrone B is associated with improved clinical outcomes in cancer patients
A prospective cohort study following 300 cancer patients receiving experimental fungal-derived therapies, including those with aszonapyrone B-containing extracts, tracking tumor response, survival, and adverse events over 2 years
Whether prior use of Neosartorya-derived compounds is associated with lower cancer incidence
A matched case-control study comparing 500 lung cancer patients with 500 healthy controls, assessing history of exposure to marine fungal products and natural compound supplements
The prevalence of anticancer effects in cell lines treated with aszonapyrone B across different laboratories
A multicenter cross-sectional study testing aszonapyrone B against a panel of 50 human cancer cell lines from different tissue origins, measuring GI50 values and resistance patterns